Abstract Body

Entry of HIV-1 is mediated by its envelope glycoproteins gp120 and gp41 (Env) that exist as a non-covalently associated trimer of heterodimers on the surface of virions. gp120 forms the outer layer and initial binding to its primary receptor CD4 creates a binding site for one of two obligatory chemokine co-receptors (CKR), CCR5 or CXCR4. CKR binding triggers refolding of gp41, enabling six-helix bundle formation that necessitates pore formation and transfer of viral core to the cell interior. gp120’s interaction with CCR5 and/or CXCR4 classifies Env into R5 or X4 phenotypes, respectively. Transmitted/founder viruses that establish infection in a new host use CCR5 while X4 emerge and predominate in late stage disease in a subset of infected individuals. R5X4 isolates use both CKRs, emerge prior to the acceleration of T cell decline and the onset of symptomatic disease, and are believed to represent an evolutionary intermediate between R5 and X4 isolates. The molecular determinants that control CKR binding by R5 and X4 gp120 molecules is well defined however, downstream events that lead to the activation of the fusion function of gp41 is still unclear. We aimed to examine how receptor-induced signals by R5X4 Envs, are transmitted to activate gp41.

Near neighbour contacts within the gp120-gp41 association interface were identified by in silico structural screen and conservative substitutions were introduced to these sites in the primary R5X4 Env of the brain derived strain, dBR07. The ability of the mutant viruses to use alternative CKRs was assessed in a TZM-bl infectivity assay and subsequently in primary CD4+ T cells and PBMCs.

Three gp41 mutants were identified with differential abilities to mediate infection via CCR5 versus CXCR4: F522Y in the FP and K574N and Q591A in heptad repeat 1. K574 and Q591 were critical for CCR5-mediated infection of PBMCs, primary CD4+ T cells and U87.CD4.CCR5 but dispensable for CXCR4-mediated infection. F522, however was essential for CXCR4-mediated infection of U87.CD4.CXCR4 cells, whereas infectivity for U87.CD4.CCR5 cells was retained. Interestingly, F522Y was not infectious for cells with low CCR5 expression in the presence of CCR5 antagonists. Importantly, K574N and Q591A retained their X4 phenotypes in the context of other R5X4 Envs.

The data suggest that R5X4 evolve distinct gp41-fusion activation pathways that sense alternative CKRs binding, and may represent a key step in the evolution of R5X4 and ultimately X4 HIV-1.